Incyte has unveiled groundbreaking findings from its STOP-HS clinical trial program, spotlighting the promising effects of the oral JAK1 selective inhibitor, povorcitinib, for treating hidradenitis suppurativa (HS). The 24-week interim results showcased significant improvements in a challenging condition that notably affects patients’ daily lives. As the study was presented at the European Association of Dermatology and Venereology (EADV) 2025 Congress, it captured the attention of dermatologists and healthcare professionals eager for advancements in HS management.
Marked Clinical Improvements
The newly released data from the STOP-HS1 and STOP-HS2 trials highlighted povorcitinib’s efficacy. By Week 24, nearly 60% of efficacy-evaluable patients treated with povorcitinib achieved HiSCR50, indicating at least a 50% reduction in symptom severity. Furthermore, an impressive subgroup achieved HiSCR75, HiSCR90, and even HiSCR100, illustrating the potential of povorcitinib to deliver profound relief. Remarkably, participants experienced notable skin pain improvement as early as Week 3, with up to 70% reporting mild or no pain by Week 24.
Safety and Tolerability
Safety data underscored the drug’s consistency and promising profile. Despite some adverse events, no participants experienced major adverse cardiovascular events or fatalities, affirming povorcitinib’s safety over the trial duration. A substantial number of patients transitioned seamlessly from placebo to povorcitinib, reflecting the drug’s tolerability and manageable side effects.
– Nearly 60% of patients achieved HiSCR50 by Week 24.
– Early and significant skin pain reduction observed from Week 3 onward.
– Safety profile affirms no major cardiovascular events or deaths.
– Povorcitinib shows promise over other conventional therapies in the market.
The STOP-HS clinical trial program has set a promising course for future hidradenitis suppurativa treatments. With these positive findings, Incyte aims to submit regulatory applications in Europe and the United States by 2026. While the complexities of HS continue to challenge healthcare providers and patients alike, povorcitinib’s targeted action brings newfound hope. With ongoing studies, povorcitinib could reshape HS therapy, offering a unique mechanism targeting JAK/STAT pathway abnormalities. As medical professionals await regulatory approval, the potential approval of povorcitinib brings refreshing optimism for improved patient outcomes.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
